INTRODUCTION AND OBJECTIVES: Focal therapy of prostate cancer might be an alternative to radical prostatectomy (RP) in treating patients with low-or intermediate-risk disease. Since MRI alone might not be sufficient in tumor location, template perineal biopsy is performed. To investigate the accuracy of locating a tumor focus we compared the results of multiparametric (mp)MRI and perineal stereotactic MRI-based TRUS-guided fusion biopsy (SFB) with the histopathology of the radical prostatectomy specimen.
INTRODUCTION AND OBJECTIVES: Focal therapy of prostate cancer might be an alternative to radical prostatectomy (RP) in treating patients with low-or intermediate-risk disease. Since MRI alone might not be sufficient in tumor location, template perineal biopsy is performed. To investigate the accuracy of locating a tumor focus we compared the results of multiparametric (mp)MRI and perineal stereotactic MRI-based TRUS-guided fusion biopsy (SFB) with the histopathology of the radical prostatectomy specimen.
METHODS: All patients who underwent a SFB in our hospital with positive findings of tumor that lead to a RP from 08/2012 to 07/2016 were included. MRI of the prostate was performed multiparametric and evaluated according to PI-RADS-classification. Lesions were marked 3-dimensionally by the radiologist. The SFB was performed using the BiopSee Ó-platform. Lesion-targeted and random biopsies were taken. The cores' positions in the prostate were recorded. Cores were embedded separately, the basal tips got marked with dye. In the histopathological report the location of tumor in the core in terms of apical, mid or base location was mentioned. Thereby tumor-foci location could be projected on the prostate in 3 dimensions. In the prostatectomyspecimen (whole mount step section) the tumor's location was reported by the pathologist. A single investigator determined the conformity of all three results visually: good (all 3 results matching), intermediate (MRI or biopsy matching with prostatectomy's result), and poor conformity (no match at all).
RESULTS: 128 patients could be included. 103 patients (79.8 %) showed good, 17 (13.2 %) intermediate, and 8 (6.2 %) poor conformity of the tumor's location. According to oncological criteria (PSA< 15 ng/ml, Gleason max. 7a, cT1-2a, unilateral disease) 67 patients (52%) would have been suitable for focal therapy. From these 50 (75%)would have been in good conformity, 12 (18%)in intermediate and 5(7,%) in poor conformity to the prostatectomy result.
CONCLUSIONS: These results show a high accuracy in locating the tumor by SFB. This could give a good base for a precise focal therapy that is not only sufficient in terms of treating all tumor cells but also in sparing surrounding structures by avoiding over-estimation of the extensions of he foci. METHODS: The records of men undergoing prostate biopsy were retrospectively collected between July 2011 and June 2016. The PI-RADS score was used to evaluate the prostate imaging according to the European Society of Urological Radiology (ESUR) guideline and PI-RADS 1~2 was defined as negative. Finally, 196 patients were MRI negative. All the patients accepted T1, T2 and DWI image. Part of them had DCE image. The mean diagnosis age is 66.6AE9.0yrs, and the median PSA is 7.44ng/ml. All patients accepted the transrectal ultrasound guided systematic 12-coreprostate biopsy.Statistical analysis was carried out with the SPSS 19.0 computer package. A P value<0.05 was considered statistically significant.
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MP03-15 THE ANALYSIS OF PROSTATE BIOPSY IN NEGATIVE MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING PATIENTS
RESULTS: There were 196 patients enrolled, with the mean diagnosis age 66.6AE9.0yrs, and the median PSA 7.44ng/ml. Of the 196 patients, there were 42(21.4%) diagnosed with prostate cancer, of which, 30 were clinically significant. The negative predictive value (NPV) was 78.6% for prostate cancer, and 84.7% for clinically significant prostate cancer.(a_image, b_image)Age and serum PSA were related with positive diagnosis. Patients over 70yrs was associated with a 2.4-fold higher risk for prostate cancer, which was 1.47 when patients were divided according to the PSA level of 4ng/ml, 4~10ng/ml, 10~20ng/ml and >20ng/ml.(c_image).
CONCLUSIONS: Clinical significant prostate cancer may exist in negative MRI patients in first time biopsy. The age and PSA level relate to the cancer detection rate.
